Crinetics Pharmaceuticals (CRNX) Cash & Equivalents (2017 - 2026)

Crinetics Pharmaceuticals has reported Cash & Equivalents for 10 years, with the latest figure at $114.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 20.91% year-over-year to $114.3 million; the trailing twelve-month figure through Mar 2026 stood at $114.3 million (up 20.91% YoY), and the FY2025 full-year result was $101.5 million, down 61.62% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $114.3 million, up from $101.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.2 billion in Q2 2025, with the low at $30.9 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $203.1 million, with a median of $110.9 million recorded in 2025.
• Year-over-year, Cash & Equivalents slumped 83.11% in 2022 and surged 861.14% in 2024.
• Tracing CRNX's Cash & Equivalents over 5 years: stood at $34.0 million in 2022, then soared by 61.59% to $54.9 million in 2023, then jumped by 381.89% to $264.5 million in 2024, then plunged by 61.62% to $101.5 million in 2025, then increased by 12.61% to $114.3 million in 2026.
• The last three Cash & Equivalents figures came in at $114.3 million (Q1 2026), $101.5 million (Q4 2025), and $110.9 million (Q3 2025), per Business Quant data.

Peer Comparison